Phase I/II trial of intravenous Doxil® and whole abdomen hyperthermia in patients with refractory ovarian cancer

International Journal of Hyperthermia

Volumn 21, Issue 4, 2005, Pages 333-347

  Secord, Angeles Alvarez ^a,b   Jones, E L ^a   Hahn, C A ^a   Petros, W P ^a   Yu, D ^b   Havrilesky, L J ^a   Soper, J T ^a   Berchuck, A ^a   Spasojevic, I ^b   Clarke Pearson, D L ^a   Prosnitz, L R ^a   Dewhirst, M W ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Doxil ; Hyperthermia; Ovarian cancer

Indexed keywords

CYTOKINE; DOXORUBICIN; LIPOSOME; PACLITAXEL; PLATINUM;

ABDOMEN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG METABOLISM; ELECTROLYTE DISTURBANCE; FAT NECROSIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTHERMIC THERAPY; HYPOKALEMIA; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; SKIN DEFECT; STOMATITIS; SUBCUTANEOUS FAT DISORDER; THERMAL INJURY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MIDDLE AGED; OVARIAN NEOPLASMS; QUALITY OF LIFE;

EID: 22144486971     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.1080/02656730500110155     Document Type: Article

References (27)

1. Alvarez AA, Clarke-Pearson DL. Platinum-resistant ovarian cancer: second-line treatment options. American Journal of Cancer 2003;2:1-13.
2. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. Journal of Clinical Oncology 2001;19:3312-3322.
3. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Journal of Clinical Oncology 1997;15:987-993.
4. Huang SK, Stauffer PR, Hong KL, Guo JWH, Phillips TL, Huang A, Papahadjopoulos D. Liposomes and hyperthermia in mice - increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Research 1994;54:2186-2191.
5. Gaber MH, Wu NZ, Hong KL, Huang SK, Dewhirst MW, Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. International Journal of Radiation Oncology, Biology and Physics 1996;36:1177-1187.
6. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Research 2000;60:4440-4445.
7. Kong G, Dewhirst MW. Hyperthermia and liposomes. International Journal of Hyperthermia 1999;15: 345-370.
8. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Research 2000;60:6950-6957.
9. Ben-Yosef R, Gipps M, Zeira M. Hyperthermia and liposomal encapsulated doxorubicin. Israel Medical Association Journal 2003;5:407-409.
10. Maruyama K, Unezaki S, Takahashi N, Iwatsuru M. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia. Biochimica et Biophysica Acta 1993;1149: 209-216.
11. Andersen A, Warren DJ, Slordal L. A sensitive and simple high-performance liquid-chromatographic method for the determination of doxorubicin and its metabolites in plasma. Therapy Drug Monitoring 1993;15: 455-461.
12. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. Journal of Clinical Oncology 2000;18:3093-3100.
13. Meyer T, Rustin GJS. Role of tumour markers in monitoring epithelial ovarian cancer. British Journal of Cancer 2000;82:1535-1538.
14. Rustin GJS, Nelstrop AE, Bentzen SM, Piccart MJ, Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Annals of Oncology 1999;10:21-27.
15. Jones EL, Samulski TV, Dewhirst MW, Alvarez-Secord A, Berchuck A, Clarke-Pearson D, Havrilesky LJ, Soper J, Prosnitz LR. A pilot phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer 2003;98:277-282.
16. Gaber MH, Hong KL, Huang SK, Papahadjopoulos D. Thermosensitive sterically stabilized liposomes - formulation and in-vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharmaceutical Research 1995;12:1407-1416.
17. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Research 2000;60:1197-1201.
18. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Research 2001;61:3027-3032.
19. Song CW. Effect of local hyperthermia on blood - flow and microenvironment - a review. Cancer Research 1984;44:4721-4730.
20. Dewhirst MW, Prosnitz L, Thrall D, Prescott D, Clegg S, Charles C, MacFall J, Rosner G, Samulski T, Gillette E, Larue S. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Seminars in Oncology 1997;24:616-625.
21. Shinkai M, Suzuki M, Iijima S, Kobayashi T. Antibody-conjugated magnetoliposomes for targeting cancer-cells and their application in hyperthermia. Biotechnology and Applied Biochemistry 1995;21:125-137.
22. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecology and Oncology 2000;78:369-372.
23. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Annals of Oncology 1999;10:1113-1116.
24. Hubert A, Lyass O, Pode D, Gabizon A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anti-Cancer Drugs 2000;11:123-127.
25. Amantea MA, Forrest A, Northfelt DW, Mamelok R. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi'ss sarcoma. Clinical Pharmacology & Therapeutics 1997;61:301-311.
26. Lyass O, Uziely B, Ben Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037-1047.
27. Hahn CA, Jones EL, Blivin JL, Sanders LL, Yu D, Dewhirst MW, Secord AA, Prosnitz LR. Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin. International Journal of Hyperthermia 2005;21:349-357.